| 0 (0%) | 08-02 12:46 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.2 | 1-year : | 0.29 |
| Resists | First : | 0.17 | Second : | 0.25 |
| Pivot price | 0.12  |
|||
| Supports | First : | 0.05 | Second : | 0.04 |
| MAs | MA(5) : | 0.06 | MA(20) : | 0.13 |
| MA(100) : | 0.25 |
MA(250) : | 0.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.4  |
D(3) : | 10.8 |
| RSI | RSI(14): 32.8 | |||
| 52-week | High : | 0.76 | Low : | 0.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SGMO ] has closed above bottom band by 25.8%. Bollinger Bands are 30.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.13 - 0.13 | 0.13 - 0.13 |
| Low: | 0.06 - 0.06 | 0.06 - 0.06 |
| Close: | 0.07 - 0.07 | 0.07 - 0.07 |
Wed, 29 Jul 2026
Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today - Stocktwits
Mon, 13 Jul 2026
Sangamo Therapeutics (SGMO) Q1 2025 earnings summary - Quartr
Wed, 24 Jun 2026
Case Summary: Sangamo Therapeutics Chapter 11 - Bondoro
Tue, 23 Jun 2026
Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell Assets - Genetic Engineering and Biotechnology News
Tue, 23 Jun 2026
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers - Fierce Biotech
Tue, 23 Jun 2026
UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 414 (M) |
| Held by Insiders | 3.7004e+008 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 33,480 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0666e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 215.3 % |
| Return on Equity (ttm) | -94.4 % |
| Qtrly Rev. Growth | 3.456e+007 % |
| Gross Profit (p.s.) | -60.16 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.09922e+007 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -90 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.91 |
| Dividend | 0 |
| Forward Dividend | 4.288e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|